Chad vs Mus: HIV-positive TB patients on ART (antiretroviral therapy)
Chad
100.0%
in 2024
Mus
100.0%
in 2024
Chad rank
1st
Mus rank
1st
HIV-positive TB patients on ART (antiretroviral therapy) over time
- Chad
- Mus
How they compare
Chad currently reports 100.0% against 100.0% in Mus, a difference of 0.0%.
Across all 14 years both countries report, Mus has been ahead every year.
Chad ranks 1st and Mus ranks 1st of 144 countries.
Mus has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Chad | Mus | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 61.1% | 89.8% | 28.7% | Mus |
| 2020s | 99.4% | 100.0% | 0.6% | Mus |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv-positive tb patients on art (antiretroviral therapy), Chad or Mus?
- Chad, at 100.0% against 100.0% in Mus as of 2024.
- What is the difference in hiv-positive tb patients on art (antiretroviral therapy) between Chad and Mus?
- 0.0%, with Chad ahead.
- How many years of comparable data are there for Chad and Mus?
- 14 years are reported by both, from 2010 to 2024.
- How do Chad and Mus rank globally for hiv-positive tb patients on art (antiretroviral therapy)?
- Chad ranks 1st and Mus ranks 1st of 144 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as HIV-positive TB patients on ART (antiretroviral therapy) (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.